David Hewings

Title: The Innovative Contributions of David Hewings

Introduction

David Hewings is a notable inventor based in Basel, Switzerland. He has made significant contributions to the field of pharmaceuticals, particularly in the development of cancer treatments. His work focuses on innovative compounds that target specific genetic mutations associated with cancer.

Latest Patents

David Hewings holds a patent for an EGFR inhibitor aimed at treating cancer. The application relates to a compound of formula (I) that includes a thiazole ring, an indazol ring, and a 6,7-dihydro-5H-pyrrolo[1,2-c]imidazole ring system. This compound is described as a selective allosteric inhibitor of various EGFR mutants, including T790M/L858R and L858R/C797S. The medical use of this compound is particularly relevant for treating non-small cell lung cancer.

Career Highlights

Throughout his career, David has worked with prominent companies in the pharmaceutical industry, including Hoffmann-La Roche Inc. and F. Hoffmann-La Roche AG. His experience in these organizations has contributed to his expertise in drug development and innovation.

Collaborations

David has collaborated with several professionals in his field, including Cosimo Dolente and Annick Goergler. These partnerships have enhanced his research and development efforts, leading to impactful advancements in cancer treatment.

Conclusion

David Hewings is a distinguished inventor whose work in developing EGFR inhibitors has the potential to significantly improve cancer treatment options. His contributions to the pharmaceutical industry reflect a commitment to innovation and patient care.